Medicare has proposed limiting coverage of Aduhelm and several prominent groups representing patients and families are pressing to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
Medicare has proposed limiting coverage of Aduhelm and several prominent groups representing patients and families are pressing to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
If you listen to the nation's largest Alzheimer's disease advocacy organizations, you might think everyone living with Alzheimer's wants unfettered access to Aduhelm, a controversial new treatment.
Medicare has proposed limiting coverage of Aduhelm, a costly new drug to treat Alzheimer’s disease, and prominent groups are pressing to make it more available. But among those facing the disease, the outlook is nuanced.